Berotralstat
Berotralstat
Berotralstat (pronunciation: beh-ROH-tral-stat) is a medication used in the treatment of Hereditary Angioedema (HAE). It is an orally administered, once-daily inhibitor of plasma kallikrein, a protein involved in inflammation and swelling in HAE.
Etymology
The name "Berotralstat" is a proprietary name given by the pharmaceutical company BioCryst Pharmaceuticals, and does not have a known etymology.
Usage
Berotralstat is used to prevent attacks of hereditary angioedema (HAE) in adults and children aged 12 years and older. HAE is a rare genetic disorder characterized by episodes of severe swelling in various parts of the body including the hands, feet, face, and airway.
Mechanism of Action
Berotralstat works by inhibiting the activity of plasma kallikrein, a protein that plays a key role in the inflammatory process that leads to swelling in HAE. By blocking this protein, Berotralstat can help to reduce the frequency and severity of HAE attacks.
Related Terms
- Plasma Kallikrein: A protein that plays a key role in the inflammatory process that leads to swelling in HAE.
- Hereditary Angioedema: A rare genetic disorder characterized by episodes of severe swelling in various parts of the body.
- BioCryst Pharmaceuticals: The pharmaceutical company that developed Berotralstat.
External links
- Medical encyclopedia article on Berotralstat
- Wikipedia's article - Berotralstat
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski